Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Razuprotafib Adjunct to Latanoprost in OHT or OAG
NCT04405245Phase 2Completed
- Sponsor
- EyePoint Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of razuprotafib in ocular hypertension, open-angle glaucoma (OAG), sponsored by EyePoint Pharmaceuticals. Started Jun 2020; status: completed.
02
Drugs
razuprotafib
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT04405245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04405245.